Citations

Clear

224 citation(s) found for "Su, Jen-Jen".

Abstract TMP6: Dural Arteriovenous Fistulas With Cognitive Impairment: Angiographic Characteristics and Treatment Outcomes
Sanchez, Sebastian , Sagues, Elena , Gudino, Andres, Saleem, Arshaq, Sheehan, Jason P. , Kim, Louis J. , Meyer, R. Michael, Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Durnford, Andrew , Polifka, Adam , Gross, Bradley A. , Alaraj, Ali , Kwasnicki, Amanda , Starke, Robert M., Chen, Stephanie H. , Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru , Winkler, Ethan A. , Zipfel, Gregory J. , Alaraj, Ali , Ojeda, Diego, Gudino, Andres , Saleem, Arshaq , Wendt, Linder , Hayakawa, M. , Chen, Ching‐Jen , Kim, Louis J. , Abecassis, Isaac Josh , Levitt, Michael R. , Lanzino, Giuseppe , Giordan, Enrico , Bulters, Diederik , Fox, W Christopher , Smith, Jessica , Gross, Bradley , Amin-Hanjani, Sepideh , van DijK, J Marc C , Phelps, Ryan , Abla, Adib A. , Du, Rose , Lai, Pui Man Rosalind , Ortega-Gutierrez, Santiago , Derdeyn, Colin P. , Samaniego, Edgar A

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tmp6 Get It

Background: Anecdotal cases of rapidly progressing dementia in patients with dural arteriovenous fistulas (dAVFs) and cortical venous drainage have been reported in small series. However, a comprehensive description of the angiographic features of this dAVFs is lacking. We conducted an analysis of the largest cohort of dAVFs presenting with cognitive impairment (dAVFs-CI), aiming to provide a better characterization of this subset of dAVFs. Methods: The CONDOR Consortium, a multicenter repository comprising 1077 dAVFs, served as the study population. Among the dAVFs, patients with dAVFs-CI were analyzed. A propensity scores matching analysis was conducted to compare dAVFs-CI with Borden type II and type III dAVFs without cognitive impairment (controls). Logistic regression was employed to identify angiographic characteristics specific to dAVFs-CI. Post-treatment outcomes were analyzed. Results: A total of 60 patients with dAVFs-CI and 60 control dAVFs were included. Outflow obstruction leading to venous hypertension was observed in all dAVFs-CI. Sinus stenosis was significantly associated with dAVFs-CI (OR 2.85, 95% CI: 1.16-7.55, p = 0.027). dAVFs-CI were more likely to have a higher number of arterial feeders (OR 1.56, 95% CI 1.22-2.05, p < 0.001) and draining veins (OR 2.05, 95% CI 1.05-4.46, p = 0.004). Venous ectasia increased the risk of dAVFs-CI (OR 2.38, 95% CI 1.13-5.11, p = 0.024). A trend toward achieving asymptomatic status at follow-up was observed in patients with successful closure of dAVFs (OR 2.86, 95% CI 0.85-9.56, p = 0.09). Discussion: Venous hypertension is a key angiographic feature dAVFs-CI. dAVFs-CI exhibit a complex angioarchitecture characterized by an increased number of arteriovenous connections and stenosed sinuses. The presence of venous ectasia further exacerbates the impaired drainage and contributes to the development of dAVFs-CI. Notably, closure of the dAVF has the potential to reverse symptoms in certain cases (Figure).
Staphylococcus aureus proteases trigger eosinophil-mediated skin inflammation
Kline, Sabrina N. , Orlando, Nicholas , Lee, Alex J. , Wu, Meng-Chen , Zhang, Jing , Youn, Christine , Feller, Laine , Pontaza, Cristina , Dikeman, Dustin , Limjunyawong, Nathachit , Williams, Kaitlin L. , Wang, Yu , Jacobsen, Elizabeth A. , Dong, Xinzhong , Archer, Nathan K. , Orlando, Nicholas A , Wu, Meng-Jen , Feller, Laine E , Jacobsen, Elizabeth A , Garza, Luis A , Archer, Nathan K , Nolan, Sabrina J. , Čiháková, Daniela , Durum, Scott Kenneth

Mayo Clinic

Proceedings of the National Academy of Sciences | January 30, 2024 | Volume: 121 | Issue: 6 | Pages: No page available

10.1073/pnas.2309243121 | PMID 38289950 Get It

Staphylococcus aureus skin colonization and eosinophil infiltration are associated with many inflammatory skin disorders, including atopic dermatitis, bullous pemphigoid, Netherton’s syndrome, and prurigo nodularis. However, whether there is a relationship between S. aureus and eosinophils and how this interaction influences skin inflammation is largely undefined. We show in a preclinical mouse model that S. aureus epicutaneous exposure induced eosinophil-recruiting chemokines and eosinophil infiltration into the skin. Remarkably, we found that eosinophils had a comparable contribution to the skin inflammation as T cells, in a manner dependent on eosinophil-derived IL-17A and IL-17F production. Importantly, IL-36R signaling induced CCL7-mediated eosinophil recruitment to the inflamed skin. Last, S. aureus proteases induced IL-36α expression in keratinocytes, which promoted infiltration of IL-17-producing eosinophils. Collectively, we uncovered a mechanism for S. aureus proteases to trigger eosinophil-mediated skin inflammation, which has implications in the pathogenesis of inflammatory skin diseases.
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001
Deschler-Baier, Barbara , Han, Yimei , Kiiskinen, Urpo , Jen, Min‐Hua , Barker, Scott , Szymczak, Sylwia, Gilligan, Adrienne M., Braud, Filippo de , Morris, John C., Worden, Francis P. , Szymczak, Sylwia

Mayo Clinic

Cancers | December 27, 2023 | Volume: 16 | Issue: 1 | Pages: 140

10.3390/cancers16010140 | PMID 38201566 Get It

Selpercatinib is indicated for locally advanced/metastatic RET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with other first-line treatments in RET-activated non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and thyroid cancer (TC). This study analyzed patient data from LIBRETTO-001 and compared the outcomes (time to treatment discontinuation {TTD}, time to next treatment or death {TTNT-D}, time to progression {TTP}, and the objective response rate {ORR}) of first-line selpercatinib (selpercatinib arm) use with the outcomes of first-line standard therapies in patients who then received selpercatinib in later lines of treatment (comparator arm). Overall, the first-line selpercatinib arm had a longer TTD, TTNT-D, and TTP versus the first-line comparator arm. The hazard ratios (HRs) for TTD were 0.29 (NSCLC), 0.15 (MTC), 0.08 (TC); for TTNT-D, the HRs were 0.48 (NSCLC), 0.11 (MTC), 0.09 (TC); and for TTP, the HRs were 0.54 (NSCLC), 0.15 (MTC), and 0.12 (TC). The ORR was higher for first-line selpercatinib versus the first-line comparator (NSCLC: 85.3% vs. 39.7%; MTC: 82.6% vs. 15.2%; and TC: 81.8% vs. 31.8%). First-line selpercatinib use is associated with improved outcomes compared to first-line comparator therapies for patients with advanced/metastatic RET-activated cancers.
Deletion of miR‐155 in microglia enhances their response to neurodegeneration and mitigates cognitive impairment in a mouse model of Alzheimer’s disease
Yin, Zhuoran , Herron, Shawn, Silveira, Sebastian , Gauthier, Christian , Mallah, Dania, Cheng, Caterina, Barry, Jen‐Li, Shorey, H. H., Durao, Ana, Jedrychowski, Mark P., Murugaiyan, Gopal , Hersh, Samuel, Ikezu, Seiko , Kleemann, Kilian L. , Margeta, Milica A. , Pitts, Kristen M. , Subramanian, Ayshwarya , Shorey, Hannah, Brandão, Wesley Nogueira , Delpech, Jean-Christophe , Madore, Charlotte , Ajay, Amrendra K. , Ikezu, Tsuneya , Butovsky, Oleg

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.076703 Get It

AbstractBackgroundMicroglia, the resident brain immune cells, play a critical role in brain homeostasis and disease progression. In neurodegenerative conditions, microglia acquire the neurodegenerative phenotype (MGnD), whose function is poorly understood. MicroRNA‐155 (miR‐155), enriched in immune cells, critically regulates MGnD. However, its role in Alzheimer’s disease (AD) pathogenesis remains unclear.MethodsWe used RNAseq and immunohistochemistry (n = 6‐8 per sex per group) to investigate the gene expression profile and AD pathology. We further utilized single‐cell RNAseq (n = 5 per group) to identify microglial clusters. Whole‐tissue proteomics (n = 4) was applied to detect the protein changes in brain milieu. Moreover, we used spontaneous alternation and forced alternation tests to evaluate the cognition (n = 33‐36).ResultWe report that microglial deletion of miR‐155 induces a pre‐MGnD activation state via interferon‐g (IFNg) signaling and blocking IFNg signaling attenuates MGnD induction and microglial phagocytosis. Single‐cell RNAseq analysis of microglia from AD mouse model identifies Stat1 and Clec2d as pre‐MGnD markers. This phenotypic transition enhances amyloid plaque compaction, reduces dystrophic neurites, attenuates plaque‐associated synaptic degradation, and improves cognition.ConclusionOur study demonstrates a novel miR‐155‐mediated regulatory mechanism of MGnD and the beneficial role of IFNg‐responsive pre‐MGnD in restricting neurodegenerative pathology and preserving cognitive function in an AD mouse model, highlighting miR‐155 and IFNg as potential therapeutic targets for AD.
APOE4 impairs microglia‐astrocyte response in Alzheimer’s disease by inducing TGFβ‐mediated checkpoints
Yin, Zhuoran , Zhang, Xiaoming , Schroeder, Caitlin M., Silveira, Sebastian , Gauthier, Christian , Mallah, Dania, Durao, Ana, Herron, Shawn, Shorey, H. H., Cheng, Yiran , Barry, Jen‐Li, Wakelin, Sam, Rhee, Jared, Yung, Anthony , Aronchik, Michael, Jain, Nimansha , Bao, Xin , Brouwer, Nieske, Deik, Amy , Baufeld, Caroline, Tanzi, Rudolph E. , Arnold, Thomas D. , Butovsky, Oleg , Rosenzweig, Neta , Kleemann, Kilian L. , Brandão, Wesley Nogueira , Margeta, Milica A. , Pitts, Kristen M. , Shorey, Hannah, Wang, Chao , Gerrits, Emma , Tenen, Daniel Geoffrey , Ikezu, Tsuneya , Santander, Nicolas G. , McKinsey, Gabriel L. , Sheppard, Dean , Krasemann, Susanne , Eggen, Bart J. L. , Clish, Clary B. , Madore, Charlotte , Holtzman, David M.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.076510 Get It

AbstractBackgroundAPOE ε4 is the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD). The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has the most enriched gene expression in neurodegenerative microglia (MGnD).MethodGeneration of CX3CR1‐CREERT2 mice crossed to APOE‐KI(E3 and E4)fl/fl: APP/PS1 and APOE‐KI(E3 and E4)fl/fl: P301S mice. Microglia and astrocytes were isolated and sequenced using either bulk RNA‐seq (MGnD‐Paradigm) or single‐cell RNA‐seq. Crosstalk between cells was determined using the NichenetR database and validated using 1) recombinant Lgals3 intracranial injection into APP/PS1 mice and 2) adoptive transfer of microglia, from APOE3‐KI, APOE4‐KI, and APOE4‐cKO mice challenged with labeled apoptotic neurons, into WT mice and isolation of astrocytes. Validation in the brain of AD donors carrying the APOE e3/3 and e3/4 alleles.ResultHere we show, in mice and in humans, a negative role of microglial APOE4 in the induction of MGnD response to neurodegeneration. Deletion of microglial APOE4 restores MGnD phenotype, associated with neuroprotection in P301S tau transgenic mice, and decreases pathology in APP/PS1 mice. MGnD‐astrocyte crosstalk associated with b‐amyloid (Ab) plaque encapsulation and clearance is mediated via Lgals3 signaling following microglial APOE4 deletion. In the brain of AD donors carrying the APOE ε4 allele, we found a sex‐dependent reciprocal induction of AD risk factors associated with suppression of MGnD genes in females, including LGALS3, as compared to APOE ε3/3 carriers. Mechanistically, APOE4‐mediated induction of ITGB8‐TGFb signaling impairs MGnD response via upregulation of TGFb‐mediated microglial homeostatic checkpoints, including INPP5D. Microglial deletion of Inpp5d restores MGnD‐astrocyte crosstalk and facilitates plaque clearance in APP/PS1 mice. Genetic and pharmacological blocking of ITGB8‐TGFb signaling enhanced MGnD response associated with increased plaque clearance in AD mice.ConclusionWe identify the microglial APOE4‐ITGB8‐TGFb pathway as a negative regulator of microglia‐astrocyte response to AD pathology, and restoring MGnD phenotype via blocking ITGB8‐TGFb signaling may provide new molecular targets to modulate and restore functional microglia in AD.
Dural Arteriovenous Fistulas With Cognitive Impairment: Angiographic Characteristics and Treatment Outcomes
Sanchez, Sebastian , Hayakawa, M. , Sheehan, Jason P. , Kim, Louis J. , Levitt, Michael R. , Meyer, R. Michael, Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Bulters, Diederik , Durnford, Andrew , Fox, W. Christopher, Polifka, Adam , Gross, Bradley A. , Kwasnicki, Amanda , Starke, Robert M., Chen, Stephanie H. , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru , Abla, Adib A. , Winkler, Ethan A. , Zipfel, Gregory J. , Alaraj, Ali , Samaniego, Edgar A , Levitt, Michael R , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Wendt, Linder , Chen, Ching‐Jen , Kim, Louis J. , Abecassis, Isaac Josh , Lanzino, Giuseppe , Giordan, Enrico , Fox, W Christopher , Smith, Jessica , Gross, Bradley , Amin-Hanjani, Sepideh , Phelps, Ryan , Du, Rose , Lai, Pui Man Rosalind , Ortega-Gutierrez, Santiago , Derdeyn, Colin P.

Mayo Clinic

Neurosurgery | December 14, 2023 | Volume: 94 | Issue: 5 | Pages: 1035-1043

10.1227/neu.0000000000002802 | PMID 38095434 Get It

BACKGROUND AND OBJECTIVES: Anecdotal cases of rapidly progressing dementia in patients with dural arteriovenous fistulas (dAVFs) have been reported in small series. However, large series have not characterized these dAVFs. We conducted an analysis of the largest cohort of dAVFs presenting with cognitive impairment (dAVFs-CI), aiming to provide a detailed characterization of this subset of dAVFs. METHODS: Patients with dAVFs-CI were analyzed from the CONDOR Consortium, a multicenter repository comprising 1077 dAVFs. A propensity score matching analysis was conducted to compare dAVFs-CI with Borden type II and type III dAVFs without cognitive impairment (controls). Logistic regression was used to identify angiographic characteristics specific to dAVFs-CI. Furthermore, post-treatment outcomes were analyzed. RESULTS: A total of 60 patients with dAVFs-CI and 60 control dAVFs were included. Outflow obstruction leading to venous hypertension was observed in all dAVFs-CI. Sinus stenosis was significantly associated with dAVFs-CI (OR 2.85, 95% CI: 1.16-7.55, P = .027). dAVFs-CI were more likely to have a higher number of arterial feeders (OR 1.56, 95% CI 1.22-2.05, P < .001) and draining veins (OR 2.05, 95% CI 1.05-4.46, P = .004). Venous ectasia increased the risk of dAVFs-CI (OR 2.38, 95% CI 1.13-5.11, P = .024). A trend toward achieving asymptomatic status at follow-up was observed in patients with successful closure of dAVFs (OR 2.86, 95% CI 0.85-9.56, P = .09) CONCLUSION: Venous hypertension is a key angiographic feature of dAVFs-CI. Moreover, these fistulas present at a mean age of 58 years-old, and exhibit a complex angioarchitecture characterized by an increased number of arteriovenous connections and stenosed sinuses. The presence of venous ectasia further exacerbates the impaired drainage and contributes to the development of dAVFs-CI. Notably, in certain cases, closure of the dAVF has the potential to reverse symptoms.